2019
Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
Maughan A, Sadigh K, Angulo-Diaz V, Mandimika C, Villanueva M, Lim JK, Ogbuagu O. Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients. BMC Infectious Diseases 2019, 19: 378. PMID: 31053098, PMCID: PMC6500032, DOI: 10.1186/s12879-019-3974-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAminoisobutyric AcidsAnti-Retroviral AgentsAntiviral AgentsBenzimidazolesCarbamatesCoinfectionCyclopropanesDrug InteractionsFemaleHepacivirusHepatitis CHeterocyclic Compounds, 4 or More RingsHIV InfectionsHumansLactams, MacrocyclicLeucineLiver CirrhosisMaleMiddle AgedProlinePyrrolidinesQuinoxalinesSofosbuvirSulfonamidesTreatment OutcomeViral LoadConceptsHIV-HCVExclusion criteriaClinical trialsHIV-HCV co-infected patientsNew hepatitis C treatmentsHepatitis C virus infectionCo-infected patientsHIV patient populationC virus infectionGlecaprevir/pibrentasvirSofosbuvir/velpatasvirExcellent cure ratesHIV viral loadMajority of patientsHepatitis C treatmentInjection drug useReal-world populationART regimenHCV agentsCurrent regimensDecompensated cirrhosisViral loadPangenotypic activityCure ratePatient population
2016
Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients
Ogbuagu O. Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients. Expert Review Of Anti-infective Therapy 2016, 14: 1113-1126. PMID: 27797606, DOI: 10.1080/14787210.2016.1255551.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHIV-1 infectionTenofovir alafenamideCombination antiretroviral medicationsEffective antiretroviral regimenKey drug interactionsSingle-tablet combinationAntiretroviral drug therapyTenofovir disoproxil fumarateDifferent patient populationsNon-nucleoside reverseClinical trial dataAntiretroviral regimenRenal safetyAntiretroviral medicationsCreatinine clearanceNeuropsychiatric toxicityDisoproxil fumaratePatient populationTreatment optionsDrug therapyDrug interactionsConference abstractsPubMed databaseTrial dataUS FDA